Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Free Cash Flow: 2016-2025

Historic Free Cash Flow for UroGen Pharma (URGN) over the last 8 years, with Sep 2025 value amounting to -$42.4 million.

  • UroGen Pharma's Free Cash Flow fell 52.58% to -$42.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$138.1 million, marking a year-over-year decrease of 43.31%. This contributed to the annual value of -$97.1 million for FY2024, which is 26.76% down from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Free Cash Flow is -$42.4 million, which was down 5.98% from -$40.0 million recorded in Q2 2025.
  • UroGen Pharma's 5-year Free Cash Flow high stood at -$13.1 million for Q4 2023, and its period low was -$42.4 million during Q3 2025.
  • Over the past 3 years, UroGen Pharma's median Free Cash Flow value was -$25.8 million (recorded in 2023), while the average stood at -$27.1 million.
  • In the last 5 years, UroGen Pharma's Free Cash Flow skyrocketed by 40.03% in 2023 and then tumbled by 67.70% in 2025.
  • Over the past 5 years, UroGen Pharma's Free Cash Flow (Quarterly) stood at -$20.3 million in 2021, then fell by 7.36% to -$21.8 million in 2022, then skyrocketed by 40.03% to -$13.1 million in 2023, then decreased by 5.23% to -$13.7 million in 2024, then plummeted by 52.58% to -$42.4 million in 2025.
  • Its last three reported values are -$42.4 million in Q3 2025, -$40.0 million for Q2 2025, and -$42.1 million during Q1 2025.